Business
Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board
The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer.
About this update from Fresenius Medical Care Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical Officer","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"As part of a planned transition Franklin W. Maddux will retire by year end","length":74,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":182,"olType":false},{"type":"text","content":"BAD HOMBURG, Germany, Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer.","length":365,"tagName":"p"},{"type":"image","alt":"Fresenius Medical Care (PRNewsfoto/Fresenius Medical Care North Am)","displaySize":"","headline":null,"caption":"Fresenius Medical Care (PRNewsfoto/Fresenius Medical Care North Am)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":86,"url":"https://media.zenfs.com/en/prnewswire.com/1ea334d2fed6b92c9bd382003cb7c081"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CAPs.jZA.Pm6wlpD_VdyoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1ea334d2fed6b92c9bd382003cb7c081","width":400,"height":86}},"href":"https://mma.prnewswire.com/media/655917/FMC_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Mr. Hugh-Jones will succeed Franklin (Frank) W. Maddux, MD (68) as part of a planned transition after Mr. Maddux informed the Supervisory Board of his intention to retire.","length":171,"tagName":"p"},{"type":"text","content":"Mr. Hugh-Jones most recently served as CEO of Volastra Therapeutics from its inception as a discovery-stage startup to a clinical-stage biotech company, advancing novel oncology assets. Prior to Volastra, he served as Chief Medical Officer at Allergan – later acquired by AbbVie –, overseeing global medical operations and leading major product launches across multiple therapeutic areas. He also held senior leadership roles at Pfizer and Sanofi, driving innovation in chronic disease care, diabetes, cardiovascular and other therapeutic areas. Mr. Hugh-Jones holds an MD from Charing Cross and Westminster Medical...